Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $16.2M of Stock
Bruce C. Cozadd sold 68,808 shares of Jazz Pharmaceuticals plc at $234.91 to $237.39 a share (average $235.95) in 4 transactions, worth $16.2M in total on Nov 6, 2026. Shares held after the trade: 357,567 (-1.6%).
Jazz Pharmaceuticals SVP, CAO Patricia Carr Sells $327K of Stock
Patricia Carr, SVP, CAO, sold 1,413 shares of Jazz Pharmaceuticals plc at $231.27 to $231.37 a share (average $231.36) in 2 transactions, worth $327K in total on Nov 4, 2026. Shares held after the trade: 6,512 (-2.4%).
Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $225K of Stock
Renee D. Gala, President & CEO, sold 1,000 shares of Jazz Pharmaceuticals plc at $225.37 a share, worth $225K in total on Nov 3, 2026. Shares held after the trade: 140,394 (-0.7%).
Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.3M of Stock
Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $215.84 a share, worth $1.3M in total on Nov 2, 2026. Shares held after the trade: 339,875 (-1.7%).
Jazz Pharmaceuticals reported its financial results for the third quarter of 2026, highlighting the acquisition of Actio Biosciences and the approval of Modeyso. The company also amended its credit agreement to refinance its term loans and increase its revolving credit facility to $885 million.
Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and the launch of Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion and highlighted the closing of its acquisition of Actio Biosciences.
“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance. At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”
Renee Gala, president and chief executive officer of Jazz Pharmaceuticals
Jazz Pharmaceuticals provided a preliminary update on its Q3 2026 financial results, estimating a $755 million pre-tax charge for acquired in-process research and development (IPR&D) related to its acquisition of Actio Biosciences. This non-deductible charge is expected to have an unfavorable impact of approximately $11.00 on both GAAP and non-GAAP adjusted earnings per share for the quarter.
Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, notified the company of her intent to retire. Her departure will be effective upon the appointment of a successor or by June 30, 2027, and the company has initiated a formal search process for her replacement.
Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $473K of Stock
Renee D. Gala, President & CEO, sold 2,000 shares of Jazz Pharmaceuticals plc at $236.40 a share, worth $473K in total on Oct 6, 2026. Shares held after the trade: 141,394 (-1.4%).
Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.38M of Stock
Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $230.33 a share, worth $1.38M in total on Oct 1, 2026. Shares held after the trade: 345,875 (-1.7%).
Jazz Pharmaceuticals $1.9B Debt Financing with Bank of America, N.A.
Jazz Pharmaceuticals' subsidiary, Jazz Financing Lux S.à r.l., entered into a repricing amendment to its credit agreement to refinance $1.895 billion in outstanding term loans. The new Tranche B-3 Dollar Term Loans extend the maturity date from May 2028 to May 2033 and reduce the interest rate margin by 50 basis points to Term SOFR plus 1.75%.